NCT02805010View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously

PHASE1UnknownINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Rheumatoid Arthritis (RA)
Interventions
DRUG

Abatacept

On Day 1, subjects will receive a single SC dose of abatacept 125mg

OTHER

Placebo

On Day 1, subjects will receive a single SC dose of placebo

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY